Total Payments
$264,128
2024 Payments
$10,125
Companies
54
Transactions
363
Medicare Patients
5,373
Medicare Billing
$504,157
Payment Breakdown by Category
Other$201,970 (76.5%)
Travel$22,600 (8.6%)
Consulting$21,699 (8.2%)
Food & Beverage$9,205 (3.5%)
Research$8,461 (3.2%)
Education$193.46 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200,170 | 50 | 75.8% |
| Travel and Lodging | $22,600 | 57 | 8.6% |
| Consulting Fee | $21,699 | 16 | 8.2% |
| Food and Beverage | $9,205 | 226 | 3.5% |
| Unspecified | $8,461 | 3 | 3.2% |
| Honoraria | $1,800 | 4 | 0.7% |
| Education | $193.46 | 7 | 0.1% |
Payments by Type
General
$255,667
360 transactions
Research
$8,461
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $164,061 | 112 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $32,630 | 39 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $21,390 | 17 | $0 (2017) |
| Eli Lilly and Company | $8,461 | 3 | $0 (2019) |
| PFIZER INC. | $6,942 | 6 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $3,150 | 1 | $0 (2022) |
| Rigel Pharmaceuticals, Inc. | $3,037 | 9 | $0 (2023) |
| BeiGene USA, Inc. | $2,767 | 4 | $0 (2024) |
| Genentech USA, Inc. | $2,740 | 5 | $0 (2018) |
| GENZYME CORPORATION | $2,503 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,125 | 27 | PFIZER INC. ($6,897) |
| 2023 | $40,481 | 49 | Seagen Inc. ($37,458) |
| 2022 | $54,117 | 53 | Seagen Inc. ($50,544) |
| 2021 | $56,518 | 79 | Seagen Inc. ($50,579) |
| 2020 | $29,197 | 54 | Seagen Inc. ($25,479) |
| 2019 | $23,884 | 36 | Takeda Pharmaceuticals U.S.A., Inc. ($14,212) |
| 2018 | $23,276 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($18,369) |
| 2017 | $26,529 | 35 | Millennium Pharmaceuticals, Inc. ($21,390) |
All Payment Transactions
363 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Ipsen Biopharmaceuticals, Inc | — | Education | In-kind items and services | $74.99 | General |
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $211.70 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 10/28/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Oncology | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.88 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.40 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $13.73 | General |
| 05/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $98.33 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $149.47 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: Oncology | ||||||
| 03/14/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $1,073.93 | General |
| Category: Oncology | ||||||
| 03/14/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 03/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: CELLT | ||||||
| 02/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $971.25 | General |
| 02/20/2024 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $16.90 | General |
| Category: Oncology | ||||||
| 01/30/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $8,461 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,300 | 9,614 | $567,505 | $123,528 |
| 2022 | 26 | 1,248 | 10,192 | $476,405 | $105,344 |
| 2021 | 23 | 1,416 | 13,140 | $457,408 | $125,462 |
| 2020 | 28 | 1,409 | 38,688 | $557,737 | $149,824 |
Total Patients
5,373
Total Services
71,634
Medicare Billing
$504,157
Procedure Codes
99
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 240 | 477 | $186,030 | $42,195 | 22.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 14 | 15 | $66,705 | $11,528 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 158 | 197 | $54,569 | $11,427 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 78 | $42,900 | $10,370 | 24.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 43 | 58 | $43,315 | $9,219 | 21.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 29 | 91 | $38,311 | $8,398 | 21.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 290 | 857 | $24,853 | $6,483 | 26.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 19 | 90 | $18,900 | $6,203 | 32.8% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 49 | 68 | $25,700 | $2,839 | 11.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $12,216 | $2,787 | 22.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 195 | $13,065 | $1,984 | 15.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 140 | 224 | $2,016 | $1,882 | 93.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 19 | 38 | $7,904 | $1,770 | 22.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 34 | $6,120 | $1,395 | 22.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $5,278 | $1,303 | 24.7% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 13 | 39 | $4,719 | $958.65 | 20.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 14 | $2,996 | $800.32 | 26.7% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 53 | 6,712 | $6,712 | $766.40 | 11.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 32 | $3,296 | $682.30 | 20.7% |
| 85046 | Red blood count automated, with additional calculations | Office | 2023 | 48 | 72 | $1,224 | $380.83 | 31.1% |
| 82565 | Blood creatinine level | Office | 2023 | 20 | 26 | $416.00 | $130.52 | 31.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 12 | 260 | $260.00 | $25.36 | 9.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 225 | 501 | $189,990 | $44,340 | 23.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 36 | 116 | $48,772 | $11,761 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 132 | 170 | $45,815 | $10,087 | 22.0% |
About Dr. Timothy Moore, MD
Dr. Timothy Moore, MD is a Hospice and Palliative Medicine healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144278243.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Moore, MD has received a total of $264,128 in payments from pharmaceutical and medical device companies, with $10,125 received in 2024. These payments were reported across 363 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($200,170).
As a Medicare-enrolled provider, Moore has provided services to 5,373 Medicare beneficiaries, totaling 71,634 services with total Medicare billing of $504,157. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Medical Oncology
- Location Columbus, OH
- Active Since 05/04/2006
- Last Updated 01/11/2023
- Taxonomy Code 207RH0002X
- Entity Type Individual
- NPI Number 1144278243
Products in Payments
- TUKYSA (Drug) $167,885
- NINLARO (Drug) $51,016
- VYXEOS (Drug) $3,150
- Tavalisse (Drug) $3,028
- Perjeta (Biological) $2,731
- XPOVIO (Drug) $2,321
- Yescarta (Drug) $1,705
- SUSTOL (Drug) $1,696
- ADCETRIS (Biological) $1,592
- BRUKINSA (Drug) $1,392
- TEVIMBRA (Drug) $1,375
- TAZVERIK (Drug) $1,250
- Aliqopa (Drug) $900.00
- KEYTRUDA (Biological) $532.47
- Lenvima (Drug) $300.60
- Pedmark (Drug) $211.70
- Cabometyx (Drug) $174.93
- clonoSEQ (Device) $170.44
- LIBTAYO (Biological) $159.75
- KISQALI (Drug) $153.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospice and Palliative Medicine Doctors in Columbus
Dr. Joseph Tu, M.d, M.D
Hospice and Palliative Medicine — Payments: $5,575
Hospice and Palliative Medicine $5,575
Jaynine Vado, Do, DO
Hospice and Palliative Medicine — Payments: $5,357
Hospice and Palliative Medicine $5,357
Dr. Roger Garcia, D.o, D.O
Hospice and Palliative Medicine — Payments: $4,099
Hospice and Palliative Medicine $4,099
David Laubli, Do, DO
Hospice and Palliative Medicine — Payments: $569.91
Hospice and Palliative Medicine $569.91
Dr. Tommy Petros, M.d, M.D
Hospice and Palliative Medicine — Payments: $431.38
Hospice and Palliative Medicine $431.38
Frank Savage, Do, DO
Hospice and Palliative Medicine — Payments: $185.83
Hospice and Palliative Medicine $185.83